MedTrace Logo

Aldara for the Treatment of Extensive Alopecia Areata

NCT00177021 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2006-11-13

No results posted yet for this study

Summary

We propose to examine the efficacy and tolerability of Aldara Cream 5% for the treatment of extensive alopecia areata. Aldara is a immune-response modifier. The drug induces the production of cytokines which are small, hormone-like proteins involved in cellular communication during immune responses. We hypothesize that this drug will effect the inflammatory cells present around hair follicles in patients with alopecia areata.

Conditions

Interventions

DRUG

Aldara Cream 5%

Sponsors & Collaborators

  • National Alopecia Areata Foundation

    collaborator OTHER

  • 3M

    collaborator INDUSTRY

  • Hordinsky, Maria K., MD

    lead INDIV

Principal Investigators

  • Maria Hordinsky, MD · University of Minnesota

  • Marna Ericson, Ph D · University of Minnesota

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2000-10-31
Completion
2002-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00177021 on ClinicalTrials.gov